|
gptkbp:instance_of
|
gptkb:DNA
|
|
gptkbp:associated_with
|
gptkb:Oncology
|
|
gptkbp:associated_with_biomarker
|
for targeted therapy
|
|
gptkbp:associated_with_drug
|
gptkb:alectinib
gptkb:ceritinib
gptkb:crizotinib
|
|
gptkbp:associated_with_prognosis
|
poor prognosis in lung cancer
|
|
gptkbp:author
|
S. Soda
|
|
gptkbp:biomarker_discovery
|
for lung cancer treatment
|
|
gptkbp:breeding_range
|
2p21
|
|
gptkbp:clinical_trial
|
ongoing trials for ALK inhibitors
target for targeted therapy
|
|
gptkbp:collaborations
|
international research teams
with pharmaceutical companies
|
|
gptkbp:diagnosis
|
for lung cancer
|
|
gptkbp:discovery
|
genomic analysis
|
|
gptkbp:discovery_year
|
gptkb:2007
|
|
gptkbp:diseases
|
gptkb:Oncology
|
|
gptkbp:ecological_role
|
tumorigenesis
|
|
gptkbp:field_of_study
|
oncology
|
|
gptkbp:funding
|
supported by cancer research grants
|
|
gptkbp:future_prospects
|
exploring new inhibitors
|
|
gptkbp:genetic_studies
|
rearrangement
5-10% in lung cancer
available for lung cancer patients
oncogenic activation
|
|
gptkbp:genomic_alteration
|
common in lung adenocarcinoma
|
|
gptkbp:has_function
|
encodes a protein
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
EML4
|
|
gptkbp:impact
|
significant in cancer research
|
|
gptkbp:innovation
|
in precision medicine
|
|
gptkbp:interacts_with
|
gptkb:ALK_protein
|
|
gptkbp:is_expressed_in
|
lung tissue
overexpressed in tumors
|
|
gptkbp:known_for
|
gptkb:EML4-ALK_fusion_gene
|
|
gptkbp:located_in
|
human chromosome 2
|
|
gptkbp:mutation_analysis
|
important for treatment decisions
|
|
gptkbp:nutritional_value
|
EF-hand domain
coiled-coil domain
EML4 protein
|
|
gptkbp:orthologs
|
found in other species
|
|
gptkbp:pathway
|
cell signaling pathway
|
|
gptkbp:patient_population
|
non-small cell lung cancer patients
|
|
gptkbp:patient_survival
|
enhanced with ALK inhibitors
|
|
gptkbp:promoter
|
gptkb:EML_family
|
|
gptkbp:provides_guidance_on
|
included in treatment protocols
|
|
gptkbp:publication
|
gptkb:Clinical_Cancer_Research
gptkb:Nature
gptkb:Cancer_Research
gptkb:Journal_of_Clinical_Oncology
gptkb:Oncogene
|
|
gptkbp:research_challenge
|
resistance to therapy
|
|
gptkbp:research_focus
|
targeting EML4-ALK fusion
|
|
gptkbp:targets
|
ALK inhibitors
|
|
gptkbp:therapeutic_strategy
|
combination therapy with chemotherapy
|
|
gptkbp:treatment
|
improved with targeted therapy
responds to ALK inhibitors
|
|
gptkbp:variant
|
fusion variant
|
|
gptkbp:bfsParent
|
gptkb:ALK
|
|
gptkbp:bfsLayer
|
6
|